BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|8|25|2249-2253

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.8, Iss.25, 2002-11, pp. : 2249-2253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BAY 43-9006: Preclinical Data

By  

Current Pharmaceutical Design, Vol. 8, Iss. 25, 2002-11 ,pp. : 2255-2257

Bentham Science Publishers

Access to resources Recommend Favorite

Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development

By  

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 938-944

Bentham Science Publishers

Access to resources Recommend Favorite

Sorafenib (BAY 43-9006): Review of Clinical Development

By  

Current Clinical Pharmacology, Vol. 1, Iss. 3, 2006-01 ,pp. : 223-228

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite